Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Latozinemab in Healthy Volunteers and FTD-GRN Carriers
NCT03636204Phase 1Completed
- Sponsor
- Alector
- Start
- Sep 2018
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial in frontotemporal dementia (FTD) comparing AL001 with Placebo (2 arms). Primary endpoints: Number of subjects with adverse events at 85 days and Number of subjects with Dose Limiting Adverse Event (DLAEs) at 85 days. Started Sep 2018; status: completed.
02
Drugs
latozinemab
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NCT03636204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03636204.